AMEX · MAIA
Healthcare · Biotechnology
$1.39
Up+$0.01 (+0.72%)
Updated Aug 22, 2026, 6:08 PM
SID Score
5.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
MAIA closed at $1.39 after 21 trading sessions, up 12.10% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $1.38 | $1.405 | $1.35 | $1.39 | 379.84K |
| Aug 20, 2026 | $1.37 | $1.40 | $1.36 | $1.38 | 223.26K |
| Aug 19, 2026 | $1.40 | $1.42 | $1.38 | $1.39 | 337.17K |
| Aug 18, 2026 | $1.39 | $1.40 | $1.36 | $1.37 | 235.78K |
| Aug 17, 2026 | $1.40 | $1.40 | $1.35 | $1.39 | 266.98K |
| Aug 14, 2026 | $1.34 | $1.40 | $1.34 | $1.40 | 569.03K |
| Aug 13, 2026 | $1.36 | $1.385 | $1.34 | $1.34 | 179.09K |
| Aug 12, 2026 | $1.35 | $1.39 | $1.335 | $1.38 | 179.64K |
| Aug 11, 2026 | $1.40 | $1.41 | $1.36 | $1.38 | 276.27K |
| Aug 10, 2026 | $1.38 | $1.41 | $1.38 | $1.41 | 202.84K |
| Aug 7, 2026 | $1.42 | $1.44 | $1.39 | $1.42 | 333.25K |
| Aug 6, 2026 | $1.47 | $1.47 | $1.38 | $1.42 | 347.41K |
| Aug 5, 2026 | $1.38 | $1.41 | $1.36 | $1.40 | 276.1K |
| Aug 4, 2026 | $1.32 | $1.38 | $1.3099 | $1.36 | 384.21K |
| Aug 3, 2026 | $1.25 | $1.32 | $1.23 | $1.32 | 650.17K |
| Jul 31, 2026 | $1.25 | $1.27 | $1.21 | $1.25 | 231.91K |
| Jul 30, 2026 | $1.22 | $1.27 | $1.19 | $1.25 | 290.6K |
| Jul 29, 2026 | $1.25 | $1.26 | $1.19 | $1.20 | 505.2K |
| Jul 28, 2026 | $1.27 | $1.31 | $1.22 | $1.24 | 520.95K |
| Jul 27, 2026 | $1.29 | $1.315 | $1.26 | $1.28 | 359.59K |
| Jul 24, 2026 | $1.28 | $1.30 | $1.24 | $1.24 | 404.72K |
The latest Smart Investors Daily articles mentioning MAIA.
MAIA research
Company profile and research snapshot.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Feb 21, 2023 | Noble Capital Markets | Outperform | — |
No generated briefing is available yet.
Benzinga · Aug 10, 2026
MAIA Biotechnology (AMEX:MAIA) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.11) by 18.18 percent. This is a 27.78 percent increase over losses of $(0.18) per share
SeekingAlpha · Jul 27, 2026
Microsoft Corporation faces AI CAPEX-driven margin pressure and FCF compression; valuation offers little safety. Click for this MSFT earnings preview.
Benzinga · Jul 8, 2026
90.5% interim disease control rate (DCR) observed with combination therapyInitial Part C efficacy observations align with previously reported THIO-101 clinical activity despite a more heavily pre-treated patient
Benzinga · Jun 25, 2026
MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that it has completed
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MAIA.
